Log in to your Guideline Central account to access additional features of this Post Surgical Pain App.
Create your free account to access premium features and additional resources only available to registered users.
Guideline Central is dedicated to providing healthcare professionals with evidence-based clinical decision-support tools that are current, practical, and easily accessible. We partner with over thirty-five medical societies and government agencies to provide quick-reference tools that physicians can rely on for credible guidance and evidence-based best practices.
The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.
Originally inspired by the Assessment in Ankylosing Spondylitis Working Group (ASAS), GRAPPA was formed in 2003. GRAPPA has pulled together many different groups, including preeminent researchers and thought-leaders in psoriatic arthritis (PsA) and psoriasis (PsO). In 2015 a team of Patient Research Partners was added to round out our perspective. The idea was to form a consortium of rheumatologists, dermatologists, radiologists, epidemiologists, patient representatives and others who would like to contribute to the field of PsA. At the inaugural meeting in 2003, a consensus exercise started the group toward prioritizing domains of inquiry in PsA and PsO. Subsequent annual meetings have focused on identifying and initiating research projects, advancing standardized criteria for psoriatic arthritis registries, and developing treatment guidelines for PsA. GRAPPA is a 501(c)3 nonprofit organization with offices in Seattle, WA and members from around the world.
Today, more than 600 thought-leaders participate in GRAPPA including rheumatologists, dermatologists, radiologists, geneticists, methodologists, epidemiologists, patient research partners, and biopharmaceutical industry representatives. Approximately 55 percent of our members live and work outside North America; creating a truly international effort.
Our goals within this project are to educate health care professionals involved in the care of people with psoriasis and psoriatic arthritis on:
|1.||The overarching principles of the management of PsA||
|2.||Efficacy and safety of new therapies recently licensed for the treatment of PsA||
|3.||New therapies currently in development of the treatment of PsA||
|4.||The effectiveness of new therapies on the different domains of PsA (peripheral arthritis, axial disease, enthesitis, dactylitis, skin and nail disease)||
|5.||Optimal treatment strategies for managing patients with PsA||
|6.||The importance of assessing comorbidities when assessing patients with PsA||
|7.||The impact of comorbidities on treatment options for those with PsA||